Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for high unmet medical needs. Its commercial portfolio includes Fanapt for acute treatment of manic or mixed episodes associated with bipolar I disorder and schizophrenia; HETLIOZ for non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY for relapsing forms of multiple sclerosis; and NEREUS for preventing vomiting induced by motion. The company also develops pipeline products such as Fanapt long acting injectable for schizophrenia, Bysanti for bipolar I disorder and major depressive disorder, HETLIOZ for jet lag and insomnia, PONVORY for psoriasis and ulcerative colitis, NEREUS for gastroparesis and atopic dermatitis, Imsidolimab for generalized pustular psoriasis, VTR-297 for hematologic malignancies, and VQW-765 for various conditions.

Vanda Pharmaceuticals Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol VNDA. Its shares are traded in United States Dollars (USD), reflecting its primary listing in the United States.

Vanda Pharmaceuticals operates in the Healthcare sector, specifically within the Biotechnology industry. This means the company is involved in using biological processes and organisms to develop therapies, particularly for conditions with high unmet medical needs.

Vanda Pharmaceuticals Inc. is headquartered in the United States, as indicated by its country of incorporation. The company focuses on developing and commercializing therapies globally, addressing high unmet medical needs worldwide. Its products target conditions such as bipolar disorder, schizophrenia, sleep disorders, multiple sclerosis, and motion sickness, among others.

Vanda Pharmaceuticals' commercial portfolio includes several key products: Fanapt (iloperidone) for acute treatment of manic or mixed episodes associated with bipolar I disorder and schizophrenia; HETLIOZ (tasimelteon) for non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY (ponesimod) for relapsing forms of multiple sclerosis; and NEREUS (tradipitant) for preventing vomiting induced by motion. The company also has a pipeline of investigational therapies targeting additional indications such as jet lag, insomnia, psoriasis, ulcerative colitis, gastroparesis, atopic dermatitis, and generalized pustular psoriasis.